Get the Stockscreener App
38.90
1.27%
-0.50
Pre-market:
39.44
0.54
+1.39%
Qiagen Nv stock is traded at $38.90, with a volume of 1.07M.
It is down -1.27% in the last 24 hours and down -2.90% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$39.40
Open:
$39.12
24h Volume:
1.07M
Relative Volume:
1.01
Market Cap:
$8.41B
Revenue:
$1.97B
Net Income/Loss:
$92.93M
P/E Ratio:
95.67
EPS:
0.4066
Net Cash Flow:
$459.60M
1W Performance:
-2.46%
1M Performance:
-2.90%
6M Performance:
-18.42%
1Y Performance:
-14.61%
1-Day Range:
$38.75
$39.48
1-Week Range:
$38.75
$40.00
52-Week Range:
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
38.90 | 8.41B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
508.90 | 191.99B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.09 | 145.87B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
117.33 | 33.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
406.29 | 33.04B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
181.43 | 31.99B | 15.41B | 1.37B | 2.11B | 7.50 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now? - Nasdaq
Digital Genome Market to Witness Remarkable Growth with QIAGEN, GenomeMe Inc., NanoString Technologies - openPR
The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses - Yahoo Finance
Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
FDA clears Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B - Medical Device Network
Qiagen at TD Cowen Conference: Strategic Growth Plans Unveiled - Investing.com
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday -March 06, 2025 at 09:14 am EST - Marketscreener.com
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
QIAGEN Gets US FDA Clearance for Second QIAstat-Dx Mini Gastrointestinal Panel -March 06, 2025 at 04:04 am EST - Marketscreener.com
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio - Silicon Canals
How QIAGEN's Latest FDA Win Strengthens Its $4.6B Diagnostic Empire - StockTitan
Market is not liking Qiagen's (NYSE:QGEN) earnings decline as stock retreats 4.7% this week - Simply Wall St
Analyzing Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN) - Defense World
QIAGEN Announces Managerial Transactions Involving Performance Stock Units - TipRanks
QIAGEN Announces Managerial Stock Transaction - TipRanks
Qiagen Announces Managerial Stock Unit Grant - TipRanks
QIAGEN Announces Manager’s Transaction with Restricted Stock Units Grant - TipRanks
Qiagen Announces Managerial Transaction Involving Restricted Stock Units - TipRanks
Qiagen N.V. (QGEN): Among the Cash-Rich Mid Cap Stocks to Buy Now - MSN
Relative Strength Alert For Qiagen - Nasdaq
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
BioMérieux: complaint lodged by German company Qiagen -March 03, 2025 at 05:57 am EST - Marketscreener.com
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing - sharewise
Qiagen Files Patent Infringement Complaint in Germany Against bioMerieux -March 03, 2025 at 05:02 am EST - Marketscreener.com
What is Zacks Research’s Estimate for Qiagen Q1 Earnings? - Defense World
QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology - Nasdaq
Qiagen Takes Legal Action To Defend Quantiferon Intellectual Property -March 03, 2025 at 01:04 am EST - Marketscreener.com
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing | StreetInsider.com - Financial Content
Zacks Research Issues Negative Estimate for Qiagen Earnings - Defense World
Zacks Research Forecasts Qiagen's Q4 Earnings (NYSE:QGEN) - MarketBeat
Qiagen (NYSE:QGEN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Qiagen (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages - Defense World
Qiagen stock touches 52-week low at $38.48 amid market shifts - Investing.com
Qiagen stock touches 52-week low at $38.48 amid market shifts By Investing.com - Investing.com South Africa
Qiagen N.V.: Some Clarity Needed Before Buying The Dip (NYSE:QGEN) - Seeking Alpha
Genetic Testing Market Future Business Opportunities - openPR
AlphaValue/Baader Europe Upgrades Qiagen to Buy, Trims PT -February 24, 2025 at 07:17 am EST - Marketscreener.com
Qiagen (NYSE:QGEN) Stock Rating Lowered by Baird R W - MarketBeat
Qiagen (NYSE:QGEN) Reaches New 1-Year LowHere's What Happened - MarketBeat
Qiagen (NYSE:QGEN) Rating Lowered to Neutral at Robert W. Baird - MarketBeat
Qiagen, Bio-Techne downgraded at Baird amid NIH funding concerns - MSN
QIAGEN NV : Berenberg remains its Buy rating -February 21, 2025 at 03:41 am EST - Marketscreener.com
Baird Downgrades Qiagen N.V. (BIT:1QGEN) - Nasdaq
Baird Downgrades Qiagen N.V. (QGEN) - MSN
Baird Downgrades Qiagen N.V. (BRSE:QGEN) - Nasdaq
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Baird Downgrades Qiagen N.V. (LSE:0RLT) - Nasdaq
Qiagen downgraded to Neutral from Outperform at Baird - TipRanks
QIAGEN opens new data center in Melbourne - MSN
Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials Driving The Negative Sentiment? - Simply Wall St
Institutional owners may take dramatic actions as Qiagen N.V.'s (NYSE:QGEN) recent 5.6% drop adds to one-year losses - Yahoo Finance
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):